Vitiligo: Pathomechanisms and genetic polymorphism of susceptible genes

Indian Journal of Experimental Biology

Volumn 44, Issue 7, 2006, Pages 526-539

  Shajil, E M ^a   Chatterjee, Sreejata ^a   Agrawal, Deepali ^a   Bagchi, T ^a   Begum, Rasheedunnisa ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Autoimmunity; Neural factors; Oxidative stress; Polymorphism; Vitiligo

Indexed keywords

ANIMAL; ANTIBODY PRODUCTION; APOPTOSIS; CELLULAR IMMUNITY; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; MELANOCYTE; PATHOLOGY; REVIEW; VITILIGO;

ANIMALS; ANTIBODY FORMATION; APOPTOSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, CELLULAR; LINKAGE (GENETICS); MELANOCYTES; POLYMORPHISM, GENETIC; VITILIGO;

EID: 33745918316     PISSN: 00195189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Ortonne J P & Bose S K, Vitiligo: Where do we stand? Pigment Cell Res, 8 (1993) 61.
2. Le Poole I C, Das P K, Van Den Wijngaard R M, Bose J D & Westerhof W, Review of the etiopathomechanism of vitiligo: A convergence theory, Exp Dermatol, 2 (1993) 146.
3. Lerner A B, Vitiligo, J Invest Dermatol, 32 (1959) 285.
4. Mehta N R, Shah K C, Theodore C, Vyas V & Patel A, Epidemiological study of vitiligo in Surat area, South Gujarat, Indian J Med Res, 61 (1973) 145.
5. Njoo M D & Westerhof W, Vitiligo: Pathogenesis and treatment, Am J Clin Dermatol, 2 (2001) 167.
6. Handa S & Kaur I, Vitiligo: Clinical findings in 1436 patients, J Dermatol, 10 (1999) 653.
7. Valia A K & Dutta P K, IADVL Text book and atlas of dermatology, (Bhalani Publishing House, Mumbai) 1996, 500.
8. Taieb A, Intrinsic and extrinsic pathomechanisms in vitiligo, Pigment Cell Res, 8 (2000) 41.
9. Nordlund J J & Lerner A B, Vitiligo. Is it important? Arch Dermatol, 118 (1982) 5.
10. Nath S K, Majumder P P & Nordlund J J, Genetic epidemiology of vitiligo: Multilocus recesssivity cross validated, Am J Hum Genet, 55 (1994) 981.
11. th edition (McGraw Hill Inc, New York) 1999, 261.
12. Hearing VJ, The regulation of melanin production, in The Pigmentary system: Physiology and pathophysiology (Oxford University press, New York) 1999.
13. Cucchi M L, Frattini P, Santagostino G & Orecchia G, Higher plasma catecholamines and metabolite level in the early phase of non-segmetal vitiligo, Pigment Cell Res, 13 (2000) 28.
14. Cucchi M L, Frattini P, Santagostino G, Preda S & Orecchia G, Catecholamines increase in the urine of non-segmental vitiligo especially during its active phase. Pigment Cell Res, 16 (2003) 111.
15. Schallreuter K U, Wood J M, Ziegler I, Lemke K R, Pittelkow M R, Lindsey N J & Gutlich M, Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo, Biochim Biophys Acta, 2 (1994a) 181.
16. Schallreuter K U, Wood J M, Pittelkow M R, Gutlich M, Lemke K R, Rodl W, Swanson N N, Hitzemann K & Ziegler I. Regulation of melanin biosynthesis in human epidermis by tetrahydrobiopterin, Science, 263 (1994b) 1444.
17. Bindoli A, Rigobello M P & Deeble D J, Biochemical and toxicological properties of the oxidation products of catecholamines, Free Rad Biol Med, 13 (1992) 391.
18. Schallreuter K U, Wood J M, Pittelkow M R, Buttner G, Swanson N, Korner C & Ehrke C. Increased monoamine oxidase A activity in the epidermis of patients with vitiligo, Arch Dermatol Res, 288 (1996) 14.
19. Le Poole I C, van den Wijngaard R M, Smit N P, Oosting J, Westerhof W & Pavel S Catechol O methyltransferase in vitiligo, Arch Dermatol Res, 286 (1994) 81.
20. Mozzanica N, Villa M L, Foppa S, Vignati G, Cattaneo A, Diotti R & Finzi A F, Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligo, J Am Acad Dermatol, 1 (1992) 693.
21. Al'Abadie M S, Senior H J, Bleehen S S & Gawkridger D J, Neuropeptide and neuronal marker studies in vitiligo, Br J Dermatol, 131 (1994) 160.
22. Liu P Y, Bondesson L, Loentz W & Tohansson O, The occurrence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: A case - control study, Arch Dermatol Res, 288 (1996) 670.
23. Covelli V & Jirillo E, Neuropeptides with immunoregulatory function: Current status of investigations, Funct Neurol, 3 (1988) 253.
24. Maresca V, Roccella M, Roccella F & Camera E, Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo. J Invest Dermatol, 109 (1997) 945.
25. 2 stress, J Invest Dermatol, 122 (2004) 307.
26. Schallreuter K U, Moore J, Wood J M, Beazley W D & Gaze D C, In vivo and in vitro evidence for hydrogen peroxide accumulation in the epidermis of patients of vitiligo and its successful removal by UVB activated pseudocatalase, J Invest Dermatol Symp Proceed, 4 (1999) 91.
27. Schallreuter K U, Wood J M & Berger J, Low catalase levels in the epidermis of patients with vitiligo, J Invest Dermatol, 6 (1991) 1081.
28. Dell'Anna M L, Maresca V, Brigandi S, Camrea E, Falchi M & Picardo M. Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo, J Invest Dermatol, 4 (2001) 908.
29. Agrawal D, Shajil E M, Marfatia Y S & Begum R, Study of the antioxidant status of vitiligo patients of different age groups in Baroda, Pigment Cell Res, 17 (2004) 289
30. Agrawal D, Antioxidant status of vitiligo patients relative to controls, M. Phil Dissertation, M.S. University of Baroda, Vadodara, 2002.
31. Shajil E M & Begum R, Antioxidant status of segmental and non-segmental vitiligo, Pigment Cell Res, 19 (2006) 179.
32. Schallreuter K U, Hordinsky M K & Wood J M, Thioredoxin reductase-Role in free radicals reduction in different hypopigmentation disorders, Arch of Dermatol, 123 (1987) 5.
33. Schallreuter K U & Pittelkow M R, Defective calcium uptake in keratinocyte cell cultures from vitiliginous skin, Arch Dermatol Res, 3 (1988) 137.
34. Shajil E M, Sahani M, Mistry N, Sheril A & Begum R, Evaluation of oxidative stress, autoimmune and neurochemical hypotheses in Baroda vitiligo patients, poster presented to the first conference of Asian Society for Pigment Cell Research, New Delhi, India, 1-2 February, 2005.
35. Kemp E H, Gawkrodger D J, MacNeil S, Watson P F & Weetman A P, Detection of tyrosinase autoantibodies in vitiligo patients using 35S-labelled recombinant human tyrosinase in radioimmunoassay, J Invest Dermatol, 109 (1997) 69.
36. Kemp E H, Gawkrodger D J, Watson P F & Weetman A P, Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: A sensitive and quantitative radioimmunoassay (RIA), Clin Exp Immunol, 114 (1998a) 333.
37. Kemp E H, Waterman E A, Gawkrodger, D J, Watson P F & Weetman A P, Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay, Br J Dermatol, 139 (1998b) 798.
38. Hedstrand H, Ekwall O, Olsson M J, Landgren E, Kemp E H., Weetman A P, Perheentupa J, Husebye E, Gustafsson J, Betterle C, Kampe O & Rorsman F, The transcription factors SOX9 and SOX10 are melanocyte autoantigens related to vitiligo in autoimmune polyendocrine syndrome type 1, J Biol Chem, 276 (2001) 35390.
39. Ongenae K, Van Geel N & Naeyaert J M, Evidence for an autoimmune pathogenesis of vitiligo, Pigment Cell Res, 2 (2003) 90.
40. Harning R, Cui J & Bystryn J C, Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo, J Invest Dermatol, 97 (1991) 1078.
41. Gilhar A, Zelickson B, Ulman Y & Etzioni A, In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo, J Invest Dermatol, 105 (1995) 683.
42. Kemp E H, Waterman E A, Hawes B E, O'Neill K, Gottumukkala R V, Gawkrodger D J, Weetman A P & Watson P F, The melanin concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo, J Clin Invest, 109 (2002) 923.
43. Mandry R C, Ortiz L J, Lugo-Somolinos A & Sanchez J L. Organ-specific autoantibodies in vitiligo patients and their relatives, Int J Dermatol, 35 (1996) 18.
44. Kemp E H, Waterman E A & Weetman A P, Immunological pathomechanisms in vitiligo, Expert Rev Mol Med, 23 (2001) 1.
45. Cui J, Harning R, Henn M & Bystryn J C, Identification of pigment cell antigens defined by vitiligo antibodies, J Invest Dermatol 98 (1992) 162.
46. Norris D A, Kissinger R M, Naughton G K & Bystryn J C, Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocyes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity, J Invest Dermatol, 90 (1988) 783
47. Le Poole I C, Van den Vijngaard R M, Westerhoff W & Das P K, Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance, Am J Pathol, 148 (1996) 1219
48. Van den Wijngaard R M, Wankowics-Kalinska A, Le Poole I C, Tigges B, Westerhof W & Das P K, Local immune response in skin of generalized vitiligo patients: Destruction of melanocytes is associated with the prominent presence of CLA+T cells at the perilesional site, Lab Invest 80 (2000) 1299.
49. Stites D P, Terr A I & Parslow T G, Clinical laboratory methods for detection of cellular immunity in Basic and Clinical Immunology, (Appleton and Lange, Norwalk, CT) 1994, 199.
50. D'Amelio R, Frati C, Fattarossi A & Aiuti F. Peripheral T cell subset imbalance in patients with vitiligo and in their apparently healthy first degree relatives, Ann Allergy, 65 (1990) 143.
51. Halder R M, Walters C S, Johnson B A, Chakrabarty S G & Kenney J A, Jr. Aberrations in T lymphocytes and natural killer cells in vitiligo: A flow cytometric study, J Am Acad Dermatol, 14 (1986) 733.
52. Badri A M, Foulis A K, Todd P M, Gariouch J J, Gudgeon J E, Stewart D G, Gracie J A & Goudie R B, Abnormal expression of MHC class II and ICAM I by melanocytes in vitiligo, J Pathol, 169 (1993) 203.
53. Ogg G S, Rod Dunbar P, Romero P, Chen J L & Cerundolo V, High frequency of skin homing melanocyte specific cytotoxic T lymphocytes in autoimmune vitiligo, J Exp Med, 188 (1998) 1203.
54. Yee C, Thompson J A, Roche P, Byrd D R, Lee P P, Piepkom M, Kenyon K, Davis M M, Riddel S R & Greenberg P D, Melanocyte destruction after antigen specific immunotherapy of melanoma: Direct evidence of T cell mediated vitiligo, J Exp Med 192 (2000) 1637.
55. Durham-Pierre D G, Walters C S & Halder R M, Natural killer cell and lymphokine-activated killer cell activity against melanocytes in vitiligo, J Am Acad Dermatol, 33 (1995) 26.
56. + T cell subset and evidence for peripheral T-cell activation, Int J Dermatol, 31 (1992) 321.
57. Mahmoud F, Abul H, Haines D, Al Saleh C, Khajeji M & Whaley K, Decreased total numbers of peripheral blood lymphocytes with elevated percentages of CD4pCD45ROp and CD4pCD25p of T-helper cells in non-segmental vitiligo. J Dermatol 29 (2002) 68.
58. Mahmoud F, Abul H, al-Saleh Q, Haines D, Burleson J & Morgan G. Peripheral T-cell activation in non-segmental vitiligo, J Dermatol, 25 (1998) 637.
59. Yu H S, Chang K L & Yu C L, Alterations in IL-6, IL-8, GM-CSF, TNF alpha, and IFN gamma release by peripheral mononuclear cells in patients with active vitiligo, J Invest Dermatol, 108 (1997) 527.
60. Caixia T, Hongwen F & Xiran L, Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo, J Dermatol Sci, 21 (1999) 59.
61. Huang C L, Nordlund J J & Boissy R, Vitiligo: a manifestation of apoptosis? Am J Clin Dermatol, 3 (2002) 301.
62. Moretti S, Spallanzani A & Amato L, New insights into the pathogenesis of vitiligo: Imbalance of epidermal cytokines at sites of lesions, Pigment Cell Res, 15 (2002) 87.
63. Katoch B, Sebastian S, Sahdev S, Padh H, Hasnain S E & Begum R, Programmed cell death and its clinical implications, Indian J Exp Biol, 40 (2002) 513.
64. Zhang X J, Chen J J & Liu J B, The genetic concept of vitiligo, J Dermatol Sci, 39 (2005) 137.
65. Ahonen P, Myllarniemi S, Sipila I & Perheentupa J, Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy APECED) in a series of 68 patients, N Engl J Med, 322 (1990) 1829.
66. Nagamine K, Peterson P & Scott H S. Positional cloning of the APECED gene, Nat Genet, 17 (1997) 393
67. Vaidya B, Imrie H, Geatch D R, Perros P, Ball S G, Baylis P H & Carr D, Association analysis of the Cytotoxic T Lymphocyte Antigen-4 (CTLA 4) and Autoimmune Regulator-I (AIRE-I) genes in sporadic autoimmune Addison's disease, J Clinical Endocrin Metabol, 85 (2000) 688.
68. Gribben J G, Freeman G J & Boussiotis V A, CTLA-4 mediates antigen-specific apoptosis of human T cells, Proc Natl Acad Sci USA, 92 (1995) 811.
69. Blomhoff A, Kemp E H & Gawkrodger D J, CTLA4 polymorphisms are associated with vitiligo in patients with concomitant autoimmune diseases, Pigment Cell Res, 18 (2005) 55.
70. Casp C B, She J X & McCormack W T, Genetic association of the catalase gene (CAT) with vitiligo susceptibility, Pigment Cell Res, 15 (2002) 62.
71. Lachman H M, Morrow B, Shprintzen R, Veit S, Parsia S S, Faedda G, Goldberg R, Kucherlapati R & Papolos D F, Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome, Am J Med Genet, 67 (1996) 468.
72. Pavel S, Muskiet F A J, De Lay L, The T H & Van der Slik W, Identification of three indolic compounds on a pigmented melanoma cell culture supernatant by gas chromatography-mass spectrometry, J Cancer Res Clin Oncol, 105 (1983) 275.
73. Tursen U, Kaya T I, Erdal M E, Derici E, Gunduz O & Ikizoilu G. Association between catechol-O-methyltransferase polymorphism and vitiligo, Arch Dermatol Res, 294 (2002) 143.
74. Pamer E & Cresswell P, Mechanisms of MHC class I-restricted antigen processing, Ann Rev Immunol, 16 (1998) 323.
75. Casp C B, She J X & McCormack W T. Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo, Genes Immun, 4 (2003) 49.
76. Jimenez-Cervantes C, Germer S, Gonzalez P & Sanchez J, FEBS Lett, 508 (2001) 44.
77. Sturm R A, Melanogenesis is regulated by the binding of α melanocyte-stimulating hormone (a MSH) and of ASIP (Agouti Signaling Protein), Melanoma Res, 12 (2002) 405.
78. Suzuki I, Tada A, Ollmann M M, Barsh G S, Im S, Lamoreux M L, Hearing V J, Nordlund J J & Abdel-Malek Z A, Agouti signaling protein inhibits melanogenesis and the response of human melanocytes to alpha-melanotropin, J Invest Dermatol, 108 (1997) 838.
79. Scott M C, Suzuki I & Abdel-Malek Z A, MC IR mRNA expression is down regulated by ASIP, Pigment Cell Res, 15 (2002) 433.
80. Na G Y, Lee K H, Kim M K, Lee S J, Kim D W & Kim J C, Polymorphisms in Melanocortin-1 receptor (MCIR) and Agouti Signaling Protein (ASIP) genes in Korean vitiligo patients, Pigment Cell Res, 16 (2003) 383.
81. Papadopoulos K I, Melander O, Orho-Melander M, Groop L C, Carlsson M & Hallengren B, Angiotensin converting enzyme (ACE) gene polymorphism in sarcoidosis in relation to associated autoimmune diseases, J Intern Med, 247 (2000) 71.
82. Scholzen T E, Stander S, Riemann H, Brzoska T & Luger T A. Modulation of cutaneous inflammation by angiotensin-converting enzyme, J Immunol, 170 (2003) 3866.
83. Jin S Y, Park H H, Li G Z, Lee H J, Hong M S & Hong S J, Association of angiotensin converting enzyme gene I/D polymorphism of vitiligo in Korean population, Pigment Cell Res, 17 (2004) 84.
84. Nagai K, Ichimiya M, Yokoyama K, Hamamoto Y & Muto M, Successful treatment of non-segmental vitiligo: systemic therapy with sex hormone - thyroid powder mixture, Horm Res, 54 (2000) 316.
85. Jin S Y, Park H H, Li G Z, Lee H J, Hong M S, Park H J, Park H K, Seo J C, Yim S V, Chung J H & Lee MH, Association of estrogen receptor 1 intron 1 C/T polymorphism in Korean vitiligo patients, J Dermatol Sci, 35 (2004) 181.
86. Hill R J, Zozulya S, Lu Y L, Ward K, Gishizky M & Jallal B, The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T cell activation, Exp Hematol, 30 (2002) 237.
87. Palacios E H & Weiss A, Function of the Src-family kinases, Lck and Fyn in T-cell development and activation, Oncogene, 23 (2004) 7990.
88. Bottini N, Musumeci L & Alonso A, A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes, Nat Genet, 36 (2004) 337.
89. Canton I, Akhtar S, Gavalas N G, Gawkrodger D J, Blomhoff A, Watson P F & Weetman A P, A single nucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN 22) confers susceptibility to generalized vitiligo, Genes Immun, 6 (2005) 584.
90. Arcos-Burgos M, Parodi E, Salgar M, Bedoya E, Builes J J, Jaramillo D, Ceballos G, Uribe A, Rivera N, Rivera D, Fonseca I, Camargo M & Palacio L G, Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA, Hum Genet, 110 (2002) 334.
91. Al-Fouzan A, al-Arbash M, Fouad F, Kaaba S A, Mousa M A & al-Harbi S A, Study of HLA class I/IL and T lymphocyte subsets in Kuwaiti vitiligo patients, Eur J Immunogenet, 22 (1995) 209.
92. Orecchia G, Perfetti L, Malagoli P, Borghini F & Kipervarg Y, Vitiligo is associated with a significant increase in HLA-A30, Cw6 and Dqw3 and a decrease in C4AQ0 in northern Italian patients, Dermatology, 185 (1992) 123.
93. Zamani M, Spaepen M, Sghar S S, Huang C, Westerhof W, Nieuweboer-Krobotova L & Cassiman J J, Linkage and association of HLA class II genes with vitiligo in a Dutch population, Br J Dermatol, 145 (2001) 90.
94. Nath S K, Kelly J A, Namjou B, Lam T, Bruner G R & Scofield R H, Evidence for a susceptibility gene, SLEV1, on chromosome 17q13 in families with vitiligo-related systemic lupus erythematosus, Am J Hum Genet, 69 (2001) 1401.
95. Fain P R, Gowan K & LaBerge G S. A genome wide screen for generalized vitiligo: Confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci, Am J Hum Genet, 72 (2003) 1560.
96. Alkhateeb A, Stetler G L, Old W, Talbert J, Uhlhorn C & Taylor M, Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3-p32.2, Hum Mol Genet, 11 (2002) 661.
97. Spritz R A, Gowan K, Bennett D C & Fain P R. Novel vitiligo susceptibility loci on chromosomes 7 (ASI2) and 8 (ASI3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis, Am J Hum Genet, 74 (2004) 188.
98. Chen J J, Huang W, Gui J P, Yang S, Zhou F S & Xiong Q G. A novel linkage to generalized vitiligo on 4q13-q21 identified in a genome-wide linkage analysis of Chinese families, Am J Hum Genet, 76 (2005) 1057.
99. Schallreuter K U. Successful treatment of oxidative stress in vitiligo, Skin Pharmacol Appl Skin Physiol, 12 (1999) 132.
100. Rokos H, Beazley W D & Schallreuter K U, Oxidative stress in vitiligo. Photo-oxidation of pterins produces hydrogen peroxide and pterin-6- carboxylic acid, Biochem Biophys Res Commun, 292 (2002) 805.
101. Gibson A & Lilley E, Superoxide anions, free radical scavengers, and nitrergic neurotransmission, Gen Pharmacol, 28 (1997) 489.
102. Jimbow K, Chen H, Park J S & Thomas P D, Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo, Br J Dermatol, 144 (2001) 55.
103. Koca R, Armutcu H, Altinyazar H C & Gurel A, Oxidant antioxidant enzymes and lipid peroxidation in generalized vitiligo, Clin Exp Dermatol, 29 (2004) 406
104. Okamoto T, Irie R F, Fujii S, Huang S K, Nizze A J, Morton D L & Hoon D S B, Anti-tyrosinase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy, J Invest Dermatol, 111 (1998) 1034.
105. Zhang X J, Liu H S, Liang Y H, Sun L D, Wang J Y & Yang S, Association of HLA class I alleles with vitiligo in Chinese Hans, J Dermatol Sci, 35 (2004) 165.
106. Fain P R, Babu S R, Bennet D C & Spritz R A, HLA class II haplotype DRB1*04-DQB1*0301 contributes to risk of familial generalized vitiligo and early disease onset, Pigment Cell Res, 19 (2006) 51.
107. Yang S, Wang J Y, Gao M, Liu H S, Sun L D & He P P, Association of HLA - DQA1 and DQB1 genes with vitiligo in Chinese Hans, Int J Dermatol, 44 (2005) 1012.
108. De Vijlder H C, Westerhof W, Schreuder G M, De Lange P & Claas F H, Difference in pathogenesis between Vitiligo vulgaris and Halo nevi associated with vitiligo is supported by an HLA association study, Pigment Cell Res, 17 (2004) 270.
109. Tastan H B, Akar A, Orkunoglu F E, Area E & Inal A, Association of HLA class I antigens and HLA class II alleles with vitiligo in a Turkish population, Pigment Cell Res, 17 (2004) 181.
110. Buc M, Fazekasova H, Cechova E, Hegyi E, Kolibasova K & Ferencik S, Occurrence rates of HLA - DRB1, HLA - DQB1, and HLA - DPB1 alleles in patients suffering from vitiligo, Eur J Dermatol, 8 (1998) 13.
111. Wang Y, Xiao Y, Zhao Y M, Liu Y X, Wang L M & Gao D K, Study on association between vitiligo and HLA class I antigens, Chin J Dermatol, 33 (2000) 407.
112. Buc M, Busova B, Hegyi E & Kolibasova K, Vitiligo is associated with HLA-A2 and HLA-Dw7 in the Slovak populations, Folia Biol (Praha), 42 (1996) 23.
113. Valsecchi R, Bontempelli M, Cainelli T, Leghissa P & Di Landro A, Vitiligo is associated with a significant increase in HLA - DR6 and a decrease in DQw2 antigens in Northern Italian patients, J Eur Acad Dermatol Venereol, 5 (1995) 9.
114. Venkataram M N, White A G, Leeny W A, al Suwaid A R & Daar A S, HLA antigens in Omani patients with vitiligo, Clin Exp Dermatol, 20 (1995) 35.
115. Venneker G T, De Waal L P, Westerhof W, D'Amaro J, Schreuder G M & Asghar S S, HLA associations in vitiligo patients in the Dutch population, Dis Markers, 11 (1993) 87.
116. Ando I, Chi H I, Nakagawa H & Otsuka F, Difference in clinical features and HLA antigens between familial and non-familial vitiligo of non-segmental type, Br J Dermatol, 129 (1993) 408.
117. Schallreuter K U, Levenig C, Kuhnl P, Loliger C, Hohl-Tehari M & Berger J. Histocompatibility antigens in vitiligo: Hamburg study on 102 patients from northern Germany, Dermatology, 187 (1993) 186.
118. Poloy A, Tibor L, Kramer J, Anh-Tuan N, Kraszits E & Medgyessy I. HLA - DR1 is associated with vitiligo, Immunol Lett, 27 (1991) 59.
119. Finco O, Cuccia M, Martinetti M, Ruberto G, Orecchia G & Rabbiosi G, Age of onset in vitiligo: Relationship with HLA supratypes, Clin Genet, 39 (1991) 48.
120. Dai X, Jin P Y, Ma L & Zeng H M, A study on the association of HLA antigens with vitiligo, Chin J Dermatol, 23 (1990) 31.
121. Dunston G M & Halder R M, Vitiligo is associated with HLA - DR4 in black patients: A preliminary report, Arch Dermatol, 126 (1990) 56.
122. Foley L M, Lowe N J, Misheloff E & Tiwari J L, Association of HLA - DR4 with vitiligo, J Am Acad Dermatol, 8 (1983) 39.
123. Metzker A, Zamir R, Gazit E, David M & Feuerman E J, Vitiligo and HLA system, Dermatologica, 160 (1980) 100.
124. Kachru R B, Telischi M & Mittal K K, HLA antigens and vitiligo in an American black population, Tissue Antigens 12 (1978) 396.